Canadian officials have launched a review into the potential risk of heart problems from Chantix, Pfizer’s smoking cessation drug, which has been linked to an increased risk of heart attacks and other cardiac events among individuals with cardiovascular disease. …
Increasing questions over serious and potentially life-threatning psychological side effects of Chantix, Pfizer’s smoking cessation drug, have convinced officials in France that the drug should no longer be subsidized in the country. …
Demand for the smoking cessation drug Chantix is skyrocketing in Japan, following a recent tax increase on cigarettes and due to a lack of publicity about the drug’s links to suicide and violent behavior. …
A New Zealand government agency has reversed it’s position regarding the safety of Pfizer’s stop-smoking drug Chantix, despite concerns that the medication, which is marketed as Champix in that country, increases the risk of suicides, violence and aggressive behavior. The agency changed it’s position about the dangers of Chantix and agreed to subsidize the medication after Pfizer reduced the drug’s price and offered it in a package deal with other medications that regulators wanted available. …
A class action lawsuit has been filed in Canada by three women from British Columbia who say that Pfizer did not give enough warning about the suicidal tendencies caused by the smoking cessation drug Champix, which is sold as Chantix in the United States.…
Health Canada has issued a reminder about the potential suicide side effects associated with Champix, the Canadian version of the stop-smoking drug Chantix. Suicides and other psychiatric side effects have led the drug regulatory agency to request stronger warnings for consumers.…
The British Government has released data confirming that users of Champix, the European version of the stop-smoking drug known as Chantix in the United States, have been reporting a number of adverse reactions associated with the drug, including suicides and suicidal thoughts.…
